Insider buying last 90 days
No open-market insider purchases were filed for CYTK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Cytokinetics moved this week on third-quarter results and fresh clinical data. The company reported revenue of $47.56 million, beating estimates by $5.82 million, with an EPS of -$1.37 against expectations, and analysts are now forecasting 2027 revenues of US$443.0 million. Additional data from the ACACIA-HCM trial for aficamten were presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, showing favorable cardiac remodeling and improvements in patient-reported health status in nonobstructive HCM. A director separately disclosed a proposed sale of 5,000 shares.
The stock closed at $55.14, up 2.7% on the day, but remains below both its 50-day average of $65.34 and its 200-day average of $69.93, with the shorter average also below the longer one, consistent with a longer-run downtrend; the shares touched a 52-week low of $58.05 earlier in the week and sit near the 52-week low of $53.55. The GekkoIndex reading of 73.6 places the stock in the Buying zone. Price sits 31.9% below the Gekko Fair Value of $80.97.
Over the next 20 trading days, there is no scheduled earnings report, with the next date set for 23 February 2027, 100 days away. Smart-money activity over the past 90 days shows one Congressional buy and no sales. Seasonally, the next 20 trading days have averaged -3.3% over 5 years, rising in 2 of them, a pattern worth noting alongside the current gap to fair value.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Cytokinetics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
Below 50 and 200-day
Close $56.13 is below the 50-day ($64.11) and 200-day ($69.78) averages, and the 50-day is below the 200-day.
See the chart64.9, Accumulation
Reading 64.9 is in the Accumulation zone.
See the GekkoIndex30.6% below
Price is 30.6% below Gekko Fair Value (more than 5% below).
See fair valueMixed
Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 1 unusual options signal.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings−1.8% on average
From this point in the calendar, the next 20 trading days averaged −1.8% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Cytokinetics closed at $56.13 on Nov 13, 2026, −14.9% over the past year, inside a 52-week range of $53.55 to $88.31.
Use the left and right arrow keys to read daily values.
Put CYTK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Cytokinetics is a biopharmaceutical company centered on muscle activators and muscle inhibitors designed to treat serious, debilitating conditions in the United States. It has brought to market MYQORZO, an oral small molecule that inhibits cardiac myosin and is used for symptomatic oHCM, and this is the therapy for which the company is best recognized.
Beyond its marketed product, the company's pipeline includes Aficamten, another oral cardiac myosin inhibitor aimed at HCM, and omecamtiv mecarbil, which is being studied as a possible treatment spanning various stages of heart failure with severely reduced ejection fraction. It is also advancing Ulacamten, an oral cardiac myosin inhibitor intended to ease hypercontractility linked to heart failure with preserved ejection fraction, along with CK-089, a fast skeletal muscle troponin activator, with both of these in Phase 1 clinical trials.
The company was incorporated in 1997 and operates out of South San Francisco, California. Its shares trade on the NASDAQ under the ticker CYTK.
Cytokinetics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.9, in the Accumulation zone, down 12.2 points over five sessions.
Down 12.2 points over five sessions, from the Buying zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 43 | +2.9% | +2.9% | ||
| Accumulation (current zone) | 287 | +0.7% | −1.9% | ||
| Neutral | 346 | −0.9% | +1.0% | ||
| Distribution | 24 | −0.4% | −0.3% | ||
| Selling | 2 | Too few readings yet | |||
Average CYTK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Cytokinetics trades 30.6% below Gekko Fair Value of $80.88, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Cytokinetics shares are worth, recalculated every trading day.
$80.88
Gekko Fair Value, Nov 14, 2026
30.6% Undervalued
At the end of Aug 2026 the price was 28.6% below the estimate.
No open-market insider purchases were filed for Cytokinetics, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CYTK in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 29 |
From congressional disclosures, which report amounts as ranges.
Cytokinetics has been buying back its own shares.
From company filings.
1signal, 0% of the flagged premium in calls.
Latest: Bullish flow on Nov 12, $338K in unusual premium.
1of the funds Gekko tracks holds CYTK.
Cytokinetics reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 23, 2027
Expected after the close, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | −$1.37 est −$1.43 | $47.56M est $41.88M | −10.8% |
| Aug 6, 2026 | −$1.50 est −$1.63 | $28.62M est $17.59M | −2.7% |
| May 5, 2026 | −$1.67 est −$1.65 | $19.36M est $8.52M | +13.3% |
| Feb 24, 2026 | −$1.50 est −$1.56 | $17.76M est $6.93M | −7.9% |
| Nov 5, 2025 | −$1.54 est −$1.59 | $1.94M est $6.05M | +1.1% |
| Aug 7, 2025 | −$1.12 est −$1.34 | $66.77M est $2.07M | −2.9% |
| May 6, 2025 | −$1.36 est −$1.36 | $1.58M est $2.79M | −9.9% |
| Feb 27, 2025 | −$1.26 est −$1.17 | $16.93M est $14.26M | −1.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Cytokinetics is $109.42, +94.9% from the last close, from 17 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 17 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | H.C. Wainwright | $140 | +149.4% |
| Nov 6 | Truist Financial | $112 | +99.5% |
| Nov 6 | Citi | $105 | +87.1% |
| Nov 5 | Leerink Partners | $100 | +78.2% |
| Nov 5 | Stifel Nicolaus | $108 | +92.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Cytokinetics averaged −1.8% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −3.1% | 2 of 5 |
| Next 10 trading days | −2.3% | 2 of 5 |
| Next 15 trading days | −5.5% | 0 of 5 |
| Next 20 trading days | −1.8% | 2 of 5 |
| Next 30 trading days | +30.5% | 3 of 5 |
For scale, CYTK’s typical 20-trading-day move in either direction is about 7.8%.
Cytokinetics’s market cap is $7.82B and revenue of $113.3M over the last twelve months.
Coverage of Cytokinetics this week reads neutral: 4 positive, 5 neutral and 2 negative headlines.
Cytokinetics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Cytokinetics’s market cap is $7.82B at the Nov 13, 2026 close of $56.13, with 139.3M shares outstanding.
The consensus analyst 12-month price target for Cytokinetics is $109.42, +94.9% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Cytokinetics is undervalued: the Nov 13, 2026 close of $56.13 is 30.6% below Gekko Fair Value of $80.88. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Cytokinetics is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of −$1.41 per share on revenue of $64.28M. Cytokinetics beat the earnings estimate in 5 of its last 8 reports, moving 6.3% on average across the report.
Cytokinetics’s 52-week high is $88.31 and its 52-week low is $53.55; it closed at $56.13 on Nov 13, 2026, −14.9% over the past year. Over the last five years the shares peaked at $110.25 on Jan 8, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (smart money) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Cytokinetics over the last 30 days, with $0 of flagged premium in calls and $338K in puts. The latest, bullish flow, was on Nov 12, 2026 with $338K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.